Dianthus Therapeutics (DNTH) AI Stock Analysis

• Market Cap: $1.34B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: 17.87%
• EPS Growth: 41.27%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 39,816,223
• 10 Day Avg. Volume: 588,847
• 30 Day Avg. Volume: 1,003,841
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.31
• Enterprise Value/Revenue: 84.74
• Enterprise Value/Gross Profit: 86.50
• Enterprise Value/Ebitda: -3.17
• 1Y Price Target: $67.85
• Price Target Upside: 101.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 44 Neutral
• Price Target: $32.00 ▼(-4.96% Downside)

Dianthus Therapeutics' overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and substantial losses. The technical analysis provides a mixed outlook, with some positive momentum indicators but overall caution advised. The valuation is unattractive due to the negative P/E ratio and lack of dividend yield.

Positive Factors

Strategic Partnerships

The partnership with Nanjing Leads Biolabs for DNTH212 enhances Dianthus' product pipeline and global reach, potentially addressing multiple autoimmune indications, which could lead to significant long-term revenue growth.

Cash Position

A strong cash position provides Dianthus with the financial flexibility to invest in R&D and support its operations, ensuring a cash runway into 2028, which is crucial for sustaining long-term growth and stability.

Product Innovation

The development of DNTH212, targeting both innate and adaptive immune systems, showcases Dianthus' innovative approach in addressing autoimmune diseases, potentially leading to improved patient outcomes and market differentiation.

Negative Factors

Revenue Decline

A declining revenue trend indicates challenges in product commercialization and market penetration, which could hinder long-term financial performance and investor confidence.

Profitability Issues

Negative profit margins highlight operational inefficiencies and financial instability, which could limit the company's ability to reinvest in growth opportunities and achieve sustainable profitability.

Cash Flow Challenges

Negative cash flows indicate potential liquidity issues, impacting the company's ability to fund operations and invest in future growth, posing a risk to long-term financial health.

Dianthus Therapeutics Business Overview & Revenue Model

Company Description

Dianthus Therapeutics (DNTH) is a biotechnology company focused on developing innovative therapies for serious autoimmune diseases. The company specializes in the discovery and commercialization of monoclonal antibodies and other biologics that target specific immune pathways. Dianthus is committed to addressing unmet medical needs and enhancing patient care through its advanced therapeutic solutions in the biopharmaceutical sector.

How the Company Makes Money

Dianthus Therapeutics primarily generates revenue through the development and commercialization of its therapeutic products. The company engages in partnerships and collaborations with larger pharmaceutical firms to co-develop its drug candidates, which can provide upfront licensing fees, milestone payments, and royalties on sales. Additionally, Dianthus may receive funding through government grants or investments from venture capital firms, particularly for its early-stage research and development efforts. Its revenue model is heavily reliant on successful clinical trials and the subsequent approval of its therapies by regulatory agencies, which can lead to significant market opportunities.

Dianthus Therapeutics Financial Statement Overview

Summary

Dianthus Therapeutics faces significant financial challenges, with declining revenues and substantial losses impacting profitability. While the company maintains low leverage, its negative return on equity and cash flow issues highlight operational inefficiencies and financial instability. The high gross profit margin is a positive aspect, but overall, the financial health of the company is concerning.

Income Statement

Dianthus Therapeutics shows a declining revenue trend with a negative revenue growth rate of -25.60% in the TTM. The company has a high gross profit margin of 97.96% in the TTM, indicating efficient cost management. However, the net profit margin is significantly negative at -23.64%, reflecting substantial losses. The EBIT and EBITDA margins are also deeply negative, suggesting operational inefficiencies.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.0044, indicating minimal leverage. However, the return on equity is negative at -34.72% in the TTM, highlighting poor profitability. The equity ratio is relatively stable, suggesting a solid asset base, but the negative ROE is a concern for investors.

Cash Flow

Operating cash flow and free cash flow are both negative, with a slight improvement in free cash flow growth at 10.33% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow aligns with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.85M	6.24M	2.83M	6.42M	1.48M	0.00
Gross Profit	4.75M	6.24M	2.83M	6.27M	-544.00K	-1.98M
EBITDA	-129.59M	-101.45M	-47.82M	-29.56M	-69.12M	-72.96M
Net Income	-114.75M	-84.97M	-43.55M	-28.48M	-13.11M	-74.94M
Balance Sheet
Total Assets	326.08M	374.01M	179.41M	83.11M	9.45M	161.62M
Cash, Cash Equivalents and Short-Term Investments	257.39M	275.24M	173.72M	75.49M	176.93M	148.84M
Total Debt	1.33M	1.49M	585.00K	788.00K	0.00	0.00
Total Liabilities	23.00M	21.53M	10.54M	127.48M	26.70M	17.71M
Stockholders Equity	303.08M	352.48M	168.87M	-44.37M	172.67M	143.91M
Cash Flow
Free Cash Flow	-100.36M	-78.28M	-36.97M	-29.21M	-9.94M	-64.42M
Operating Cash Flow	-100.23M	-78.18M	-36.86M	-29.07M	-9.90M	-64.02M
Investing Cash Flow	-241.23M	-286.81M	20.25M	-59.82M	43.43M	-10.63M
Financing Cash Flow	40.70M	255.62M	133.57M	96.68M	89.60M	67.74M

Dianthus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Positive. The current price of 33.67 is below the 20-day moving average (MA) of 34.72, above the 50-day MA of 33.16, and above the 200-day MA of 23.40, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 24.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNTH.

Dianthus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JANX	―	$1.79B	―	-12.82%	―	-97.10%	-96.30%
AMLX	―	$1.51B	―	-87.42%	―	-100.08%	-2.45%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARDX	―	$1.23B	―	-39.36%	―	83.88%	15.24%
DNTH	―	$1.34B	-10.35	-34.71%	―	17.87%	41.27%
EWTX	―	$1.73B	―	-27.41%	―	―	-1.46%
BHVN	―	$1.82B	―	-295.94%	―	―	16.36%

Dianthus Therapeutics Corporate Events

Dianthus Therapeutics Signs License Agreement with Nanjing Leads

On October 16, 2025, Dianthus Therapeutics entered into a License and Collaboration Agreement with Nanjing Leads Biolabs, granting Dianthus an exclusive license outside Greater China to develop and commercialize DNTH212, a bifunctional fusion protein targeting immune system pathways. This agreement involves significant financial commitments, including up to $38 million in upfront and milestone payments, and potential royalties for Leads. The collaboration aims to enhance Dianthus’ position in the autoimmune disease therapeutics market, with DNTH212 showing potential for superior clinical efficacy compared to existing treatments.

The most recent analyst rating on (DNTH) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Dianthus Therapeutics Raises $270M Through Stock Offering

On September 9, 2025, Dianthus Therapeutics, Inc. entered into an underwriting agreement to issue and sell 6,487,879 shares of its common stock and pre-funded warrants to purchase 1,112,121 shares, raising approximately $270 million. This financial move, expected to close on September 11, 2025, is aimed at strengthening the company’s capital position and enhancing its market presence, with implications for its stakeholders and industry positioning.

The most recent analyst rating on (DNTH) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Dianthus Therapeutics Reports Positive Phase 2 Trial Results

On September 8, 2025, Dianthus Therapeutics announced positive top-line data from its Phase 2 MaGic trial for claseprubart (DNTH103) in treating generalized Myasthenia Gravis (gMG). The trial demonstrated statistically significant and clinically meaningful improvements in key efficacy endpoints, with a favorable safety profile. These results support the potential best-in-class profile of claseprubart and bolster confidence in future clinical programs.

The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Dianthus Therapeutics Reports Q2 2025 Financial Results

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases, operating primarily in the United States. In its latest earnings report for the quarter ended June 30, 2025, the company highlighted a significant increase in research and development expenses, reflecting its commitment to advancing its lead product candidate, claseprubart. Despite reporting a net loss of $31.6 million for the quarter, Dianthus maintains a strong cash position with $13.2 million in cash and cash equivalents and $244.2 million in short-term investments. The company continues to focus on its strategic initiatives, including the development of claseprubart, with total research and development expenses reaching $26.3 million for the quarter. Looking ahead, Dianthus aims to leverage its robust financial resources to advance its clinical programs and explore potential strategic partnerships to support its growth and development efforts.

Dianthus Therapeutics’ CAPTIVATE Study: A Potential Game-Changer for CIDP Treatment

The CAPTIVATE study, officially titled ‘A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),’ aims to assess the efficacy and safety of DNTH103. This study is significant as it targets CIDP, a chronic neurological disorder that affects the peripheral nerves, potentially offering new treatment options for patients.